David A Ramies

Author PubWeight™ 12.73^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	J Clin Oncol	2005	9.95
2	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.	J Clin Oncol	2005	2.51
3	Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.	Clin Cancer Res	2004	1.00